Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Pfizer tests how experimental drug PF-07976016 travels in the body

NCT ID NCT07015918

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This completed Phase 1 study looked at how the experimental drug PF-07976016 is absorbed, distributed, and removed from the body. Eight healthy male volunteers took the drug by mouth and by vein so researchers could track its path using a tiny radioactive marker. The goal was purely to understand the drug's behavior, not to treat any disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PF-07976016

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

8 people

The number who actually took part.

Started

Jun 2025

Finished

Aug 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Males, 18 to 65 years of age * BMI 17.5 to 32 kg/m2 and a total body weight \>50 kg (110 lb) * Willing and able to comply with all study procedures Exclusion Criteria: * History of irregular bowel movements or lactose intolerance * Any medical or psychiatric condition or laboratory abnormality or other condition that may increase the risk of study participation * Use of any prohibited or concomitant medication(s) * Presence of specified abnormalities on diagnostic assessments including clinical laboratory tests * Positive urine drug test * History of alcohol abuse or repeated binge drinking and/or any other illicit drug use or dependence * Use of tobacco/nicotine containing products in excess of the equivalent of 5 cigarettes/day * Previous administration of an investigational product within 30 days preceding the first dose of study medicine in this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy male volunteers are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • ICON

    Groningen, 9728 NZ, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.